● LIVE
Updated 27d ago
· 12 sources tracked
Germany's Merck boosts life sciences business with $11 billion Bio-Techne deal
German drugmaker Merck KGaA has agreed to purchase U.S.-based Bio-Techne Corp. The deal aims to strengthen Merck's position in life sciences and advanced biological research markets. This represents the company's largest acquisition in more than ten years.
What changed
Merck KGaA announced the acquisition of Bio-Techne for $11.3 billion.
Live updates
-
Merck KGaA to Acquire Bio-Techne for $11.3 Billion
confidence 100%German drugmaker Merck KGaA has agreed to purchase U.S.-based Bio-Techne Corp. The deal aims to strengthen Merck's position in life sciences and advanced biological research markets. This represents the company's largest acquisition in more than ten years.
What's confirmed:
- Merck KGaA agreed to acquire U.S. biotech firm Bio-Techne Corp for $11.3 billion.
- The purchase price is US$73 per share in cash, representing an enterprise value of EUR 9.9 billion.
- This is the largest deal for Merck KGaA in over a decade.
- Bio-Techne is based in the Twin Cities.
Still unconfirmed:
- The deal follows the recent promotion of Kai Beckmann to CEO at Merck.